PHIL Partners with Harrow to Power HarrowRx, One Prescribing Destination for Harrow’s Eye Care Portfolio - Business Wire
Business Wire · Nov 2, 2:00 PM
Harrow Launches HarrowRx Platform - Yahoo Finance
Yahoo Finance · Nov 2, 12:00 PM
Harrow Launches HarrowRx Platform - GlobeNewswire
GlobeNewswire · Nov 2, 12:00 PM
Harrow sells branded eye-care drugs in North America, including VEVYE for dry eye, IHEEZO for eye anesthesia and TYRVAYA nasal spray, and is developing G-MELT for procedural sedation.
Harrow's investment case rests on converting ophthalmology demand into accelerating revenue and profitability to meet reiterated guidance of $350 million to $365 million in revenue and $80 million to $100 million in Adjusted EBITDA. VEVYE growth, BYOOVIZ and acquired TYRVAYA support the opportunity. HarrowRx could simplify access across the portfolio, but the commercial ramp remains the decisive question. TYRVAYA's cash-funded acquisition and contingent sales milestones add financial demands.
Thesis checklist
1 risk needs attention
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Next decision point
Tests: Second half delivers 2026 guidance
Are revenue growth and profitability progressing fast enough to support management's annual guidance?
Strong, inconclusive and weak outcomes
What to look for in the result and how each would move the checklist
Price and material events
Select an event marker to read the update below. Marker colors show Thesis status.
Harrow still needs a sharp commercial ramp to deliver annual guidance
Specialty ophthalmic rollup with Phase 3-proven sedation drug racing a widening cash burn toward an NDA filing
Multi-product ophthalmic commercial roll-up with $350M+ revenue guidance bets on MELT-300 NDA to add a non-ophthalmic growth leg
MELT-300's NDA submission will test whether Harrow can convert a compounded sedation product into an FDA-approved asset atop a maturing ophthalmic commercial platform
About this history: every entry shows when the Thesis moved and what it said. The reasoning behind each move (the evidence, the analysis and the source filing) and the earnings write-ups are part of a subscription.
Dates, trials and completed outcomes are open to everyone. What each upcoming milestone hinges on is part of a subscription.
Disease areas: Other cancers, Eye diseases, Neurology and pain
Catalyst calendar · Upcoming FDA decisions · Thesis changes
Competitive landscape
4 peers tracked
Cash: Market-data provider estimate; measurement period unavailable.
Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.
Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.
Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.
Runway: No underlying guidance available.